Organization

6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Nature of Operations [Text Block]

1.   Organization

Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic biologics and innovative medicines to address serious diseases and unmet medical needs. The Company is developing the following synthetic biologic candidates: a series of monoclonal antibodies (mAbs) for the treatment of infectious diseases not adequately addressed by existing therapies and a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH). The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, amyotrophic lateral sclerosis (ALS) and fibromyalgia.

Medical Indication	Product Candidate	Status
Infectious disease	SYN-ID-001	Discovery; Collaboration with Intrexon
	(Monoclonal antibody)
Infectious disease	SYN-ID-002	Discovery; Collaboration with Intrexon
	(Monoclonal antibody)
Infectious disease	SYN-ID-003	Discovery; Collaboration with Intrexon
	(Monoclonal antibody)
PAH	SYN-PAH-001	Preclinical; Collaboration with Intrexon
	(Synthetic DNA-based therapy)
Relapsing-remitting MS	Trimesta (oral estriol)	All patients enrolled in Phase II clinical trial; dosing and monitoring underway
Cognitive dysfunction in MS	Trimesta (oral estriol)	Patient enrollment underway in Phase II clinical trial
ALS	AEN-100	Phase II/III clinical trial preparation underway
	(gastroretentive zinc acetate)
Fibromyalgia	Effirma	Partnered with Meda AB
	(oral flupirtine)